Clinical Trials Logo

Clinical Trial Summary

This study for a single-center prospective phase II randomized controlled train to assess the efficacy and safety of Induction therapy on thymoma .Methods patients with thymoma (stage Ⅲ and stage Ⅳa) were treated with 2 cycles of (NAB)-paclitaxel plus Cisolation (Paclitaxel For Injection(Aalbumin Bound)125 mg/m2 Day 1 、Day8 ,Cisplatin 75 mg/m2 Day 1of each 3-week cycle)or CEP(cisplatin 50 mg/m2 Day 1, epirubicin 75 mg/m2 Day 1,cyclophosphamide 500 mg/m2 Day 1 of each 3-week cycle). Following chemotherapy to evaluate the patient for operation. Patients without undergo surgery will be continued to receive 2 cycles of Primary chemotherap.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05816694
Study type Interventional
Source Shanghai Zhongshan Hospital
Contact Bei Xu, Ph.D
Phone 13817687547
Email xu.bei2@zs-hospital.sh.cn
Status Not yet recruiting
Phase Phase 2
Start date April 30, 2023
Completion date April 30, 2026